Plain-English translation of NCT06578052 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether irinotecan liposome combined with capecitabine can help people with advanced pancreatic cancer whose cancer has grown despite first-line treatment. The study will enroll 20 patients and follow them through about 6 cycles of treatment, plus a year of follow-up. Researchers want to see if this medication combination is safe and whether it slows or stops cancer growth.
Pancreatic cancer is very difficult to treat, and many patients' cancers stop responding to the standard first treatment. This study exists to find out if this new medication combination could give patients another effective option when their cancer progresses.
You likely qualify if…
You likely don't qualify if…
You will have a screening visit within 28 days to confirm you qualify. During the treatment phase, you will receive an intravenous infusion of one medication every 2 weeks, and take an oral medication twice daily for one week followed by a one-week break, repeating this cycle. The study plans for about 6 cycles of treatment (roughly 12 weeks), though your doctor may continue treatment longer if it's working and you tolerate it well. You will have regular clinic visits for blood tests and imaging scans to monitor how you're responding. After treatment ends, you will be followed for 12 months to check your safety and how long your cancer stays controlled.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China